Cell structure, its manufacturing method, and method for evaluating hepatotoxicity of test substance

Abstract

To provide a cell structure that is highly responsive to substances having hepatotoxicity. [Solution] A cell structure comprising cells including at least hepatocytes and vascular endothelial cells, and extracellular matrix components, the extracellular matrix components being arranged between the cells, and having a hepatic sinusoidal network between the cells.

Description

[Technical Field]

[0001] The present invention relates to a cell structure, a method for producing the same, and a method for evaluating the hepatotoxicity of a test substance. [Background technology]

[0002] Drug-induced liver injury (DILI) is a major cause of drug development and market discontinuation. DILI has a complex and diverse mechanism of action, and some toxicity is caused by biological reactions unique to humans, making it difficult to predict in advance using animal tests. Therefore, hepatoid tissue is needed as an alternative tool for predicting such toxicity unique to humans.

[0003] Known techniques for artificially producing structures that mimic biological tissue include, for example, a method for producing a three-dimensional tissue by culturing coated cells whose entire surface is covered with an adhesive film (Patent Document 1), and a method for producing a three-dimensional cellular tissue (Patent Document 2), which involves mixing cells with a cationic substance and an extracellular matrix component to obtain a mixture, collecting the cells from the mixture, and forming a cell aggregate on a substrate. The present inventors have also proposed a method for producing a three-dimensional tissue with a high collagen concentration by contacting cells with endogenous collagen, and preferably further contacting them with fibrous exogenous collagen (Patent Document 3). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Laid-Open No. 2012-115254 [Patent Document 2] International Publication No. 2017 / 146124 [Patent Document 3] International Publication No. 2018 / 143286 Summary of the Invention [Problem to be solved by the invention]

[0005] An in vitro hepatoid tissue that can reproduce higher-order tissue morphology such as vascular structure in three dimensions and enable accurate toxicity evaluation has not yet been constructed.

[0006] An object of the present invention is to provide a cell structure that is highly responsive to hepatotoxic substances and a method for producing the same. [Means for solving the problem]

[0007] That is, the present invention relates to, for example, the following inventions. [1] The cell-derived medium contains at least hepatocytes and vascular endothelial cells, and an extracellular matrix component. the extracellular matrix components are disposed between the cells; A cellular structure having a hepatic sinusoidal network between the cells. [2] The cell structure according to [1], wherein the ratio of the number of the hepatocytes to the total number of the cells is 60% or more and 80% or less. [3] The cell structure according to [1] or [2], wherein the ratio of the number of the vascular endothelial cells to the total number of the cells is 5% or more and 35% or less. [4] The cell structure according to any one of [1] to [3], wherein the extracellular matrix component is fibrous. [5] The cell structure according to any one of [1] to [4], wherein the extracellular matrix component comprises a collagen component. [6] The cell structure according to any one of [1] to [5], which contains a polyelectrolyte. [7] The cell structure according to any one of [1] to [6], wherein the extracellular matrix component comprises a fragmented extracellular matrix component. [8] The cell structure according to any one of [1] to [7], wherein the vascular endothelial cells are sinusoidal endothelial cells. [9] The cell structure according to any one of [1] to [8], wherein the cells further comprise hepatic stellate cells.

[10] a culturing step of culturing the cell structure according to any one of [1] to [9] in contact with a test substance, A method for evaluating the hepatotoxicity of a test substance, which evaluates the presence or degree of hepatotoxicity using the number of surviving cells, albumin production, adenosine triphosphate content, or hepatic sinusoidal network of the cell structure after the culture process as indicators.

[11] The method for evaluating the hepatotoxicity of a test substance according to

[10] , wherein the culturing step is carried out by culturing the cell structure in a medium containing the test substance.

[12] a contacting step of contacting cells including at least hepatocytes and vascular endothelial cells with an extracellular matrix component in an aqueous medium; a culturing step of culturing the cells contacted with the extracellular matrix component, the contacting step is carried out under conditions that suppress aggregation of the extracellular matrix components in the aqueous medium; A method for producing a cell structure, wherein the culture step is carried out under conditions suitable for culturing non-parenchymal liver cells.

[13] The method for producing a cell structure described in

[12] , wherein the extracellular matrix component is fibrous.

[14] The method for producing a cell structure according to

[12] or

[13] , wherein the contacting step is carried out by mixing the cells, the extracellular matrix component, and a polymer electrolyte.

[15] The method for producing a cell structure according to

[14] , wherein the polymer electrolyte is heparin.

[16] A method for producing a cell structure described in any of

[12] to

[15] , wherein the contacting step includes accumulating the cells and the extracellular matrix components after contacting the cells with the extracellular matrix components.

[17] The method for producing a cell structure according to any one of

[12] to

[16] , wherein the extracellular matrix component contains a collagen component.

[18] The method for producing a cell structure according to any one of

[12] to

[17] , wherein the extracellular matrix component comprises a fragmented extracellular matrix component.

[19] The method for producing a cell structure described in

[18] , wherein the fragmented extracellular matrix components are defibrated extracellular matrix components.

[20] The method for producing a cell structure according to any one of

[12] to

[19] , wherein the vascular endothelial cells are sinusoidal endothelial cells. [twenty one] The method for producing a cell structure according to any one of

[12] to

[20] , wherein the cells further comprise hepatic stellate cells. [twenty two] The method for producing a cell structure according to any one of

[12] to

[21] , wherein the culturing step is carried out in the presence of an angiogenesis promoting factor. [Effects of the Invention]

[0008] According to the present invention, it is possible to provide a cell structure that is highly responsive to hepatotoxic substances and a method for producing the same.

[0009] The cell structure of the present invention is capable of maintaining liver function for a relatively long period of time (for example, two weeks or more).The cell structure of the present invention can be used to evaluate the hepatotoxicity of a test substance. [Brief explanation of the drawings]

[0010] [Figure 1] 1 shows photographs showing the results of microscopic observation of the cell structure of Example 1 by CD31 staining and albumin staining. [Figure 2] 1 shows photographs showing the results of microscopic observation of the cell structure of Example 2 by CD31 staining and albumin staining. [Figure 3]1 shows photographs showing the results of microscopic observation of the cell structure of Example 3 by CD31 staining and albumin staining. [Figure 4] 1 shows photographs showing the results of microscopic observation of the cell structure of Example 4 by CD31 staining and albumin staining. [Figure 5] 1 shows photographs showing the results of microscopic observation of the cell structure of Example 5 by CD31 staining and albumin staining. [Figure 6] 1 shows photographs showing the results of microscopic observation of the cell structure of Comparative Example 1 stained with CD31 and albumin. [Figure 7] 1 shows photographs showing the results of microscopic observation of the cell structure of Example 6 by CD31 staining. [Figure 8] 1 shows photographs showing the results of microscopic observation of the cell structure of Example 7 by CD31 staining. [Figure 9] 1 shows photographs showing the results of microscopic observation of the cell structure of Example 8 by CD31 staining. [Figure 10] 1 is a graph showing the measurement results of albumin secretion amount. [Figure 11] 1 is a graph showing the results of evaluation of responsiveness to nefadazone. [Figure 12] 1 is a graph showing the results of evaluation of responsiveness to Troglitazone. [Figure 13] 1 shows photographs showing the results of a monocrotaline administration experiment. [Figure 14] 13 is a photograph showing the results of a monocrotaline administration experiment, and is an enlarged photograph of FIG. 13. [Figure 15] 1 is a graph showing the results of analysis of the hepatic sinusoidal network in a monocrotaline administration experiment. [Figure 16] 1 is a graph showing the results of an ATP assay in a monocrotaline administration experiment. DETAILED DESCRIPTION OF THE INVENTION

[0011] Hereinafter, embodiments of the present invention will be described in detail, but the present invention is not limited to the following embodiments.

[0012] [Cell structure] The cell structure according to this embodiment includes cells including at least hepatocytes and vascular endothelial cells, and an extracellular matrix, with the extracellular matrix arranged between the cells. The cell structure according to this embodiment can be used as a hepatoid tissue (liver model), which is a biological tissue model having a function similar to at least a portion of the function of the liver and / or a structure similar to at least a portion of the structure of the liver.

[0013] As used herein, the term "cell structure" refers to an aggregate of cells (a mass of cells) in which cells are arranged three-dimensionally, and is an aggregate artificially produced by cell culture. Extracellular matrix components may be arranged between at least some of the cells. In the cell structure, there may be portions where the cells are in direct contact with each other.

[0014] The shape of the cell structure is not particularly limited, and examples thereof include sheet-like, spherical, approximately spherical, ellipsoidal, approximately ellipsoidal, hemispherical, approximately hemispherical, semicircular, approximately semicircular, rectangular, and approximately rectangular. Here, biological tissue includes sweat glands, lymphatic vessels, sebaceous glands, etc., and has a more complex structure than cell structures. Therefore, cell structures and biological tissues can be easily distinguished. Furthermore, the cell structure may be an aggregate formed in a mass adhered to a support, or an aggregate formed in a mass not adhered to a support.

[0015] (cell) The cells may be somatic cells or germ cells. Furthermore, the cells may be stem cells or cultured cells such as primary cultured cells, subcultured cells, and cell line cells. As used herein, "stem cells" refer to cells with self-renewal and pluripotency. Stem cells include pluripotent stem cells, which have the ability to differentiate into any cell type, and tissue stem cells (also called somatic stem cells), which have the ability to differentiate into specific cell types. Examples of pluripotent stem cells include embryonic stem cells (ES cells), somatic cell-derived ES cells (ntES cells), and induced pluripotent stem cells (iPS cells). Examples of tissue stem cells include mesenchymal stem cells (e.g., bone marrow-derived stem cells), hematopoietic stem cells, and neural stem cells.

[0016] The total number of cells constituting the cell structure of this embodiment is not particularly limited, and is determined appropriately taking into consideration the thickness and shape of the cell structure to be constructed, the size of the cell culture vessel to be used for construction, etc.

[0017] In the cell structure according to this embodiment, the cells include at least hepatocytes and vascular endothelial cells.

[0018] Hepatocytes, also known as hepatocytes, are cells that have functions such as secreting bile and plasma proteins. The hepatocytes constituting the cell structure may be primary hepatocytes collected from an animal liver, cultured primary hepatocytes, a cultured cell line established from primary hepatocytes, or hepatoblasts artificially differentiated from stem cells. Primary hepatocytes include primary human hepatocytes such as PXB cells. Cultured cell lines include cell lines derived from inactivated hepatoma cells such as HepG2. Stem cells that can be differentiated into hepatoblasts include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), and mesenchymal stem cells. The hepatocytes contained in the cell structure of this embodiment are preferably non-cancerous cells such as primary hepatocytes and hepatoblasts, and PXB cells are more preferred due to their ease of handling.

[0019] The cell structure may contain one type of hepatocyte, or two or more types. For example, the cell structure may contain multiple hepatocytes with different genotypes for proteins involved in liver function. Conversely, all hepatocytes contained in the cell structure may have the same genotype for proteins involved in liver function. Examples of proteins involved in liver function include drug-metabolizing enzymes.

[0020] The ratio (X1 / X0×100) of the number of hepatocytes (X1) to the total number of cells (X0) in the cell structure may be 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, or 65% or more, and may be 95% or less, 90% or less, 80% or less, or 75% or less. From the viewpoint of being even more suitable as hepatoid tissue, the ratio (X1 / X0×100) of the number of hepatocytes (X1) to the total number of cells (X0) in the cell structure may be 60% or more and 80% or less, or 60% or more and 70% or less.

[0021] Vascular endothelial cells refer to flattened cells that form the surface of the vascular lumen. Vascular endothelial cells may be, for example, sinusoidal endothelial cells or human umbilical vein-derived endothelial cells (HUVECs). Sinusoidal endothelial cells are non-parenchymal hepatic cells (cells that make up the liver other than hepatocytes) that have a characteristic morphology different from other vascular endothelial cells, such as a collection of numerous small pores (a sieve structure) in the cytoplasm and the lack of a basement membrane. Vascular endothelial cells that form the cell structure may be primary cells (primary vascular endothelial cells) collected from the liver of an animal (e.g., human), cultured cells, cultured cell lines established from primary cells, or cells artificially differentiated from stem cells. Examples of primary vascular endothelial cells include primary sinusoidal endothelial cells, such as product number 5000 manufactured by Sciencell. Examples of cultured cell lines include product number T0056 manufactured by Applied Biological Materials. Examples of stem cells to be differentiated include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), etc. The vascular endothelial cells contained in the cell structure according to this embodiment may be non-cancerous cells.

[0022] The ratio (X2 / X0×100) of the number of vascular endothelial cells (X2) to the total number of cells (X0) in the cell structure may be 5% or more, 10% or more, 12% or more, 14% or more, 15% or more, 20% or more, or 25% or more, or may be 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, or 18% or less. From the viewpoint of being more suitable as hepatoid tissue, the ratio (X2 / X0×100) of the number of vascular endothelial cells (X2) to the total number of cells (X0) in the cell structure may be 5% or more and 40% or less, 5% or more and 35% or less, 10% or more and 35% or less, 10% or more and 25% or less, or 12% or more and 20% or less. The number of sinusoidal endothelial cells to the total number of cells in the cell structure may be within the above range.

[0023] The cells in the cell structure of this embodiment may further include hepatic stellate cells, making it even more suitable as hepatoid tissue. Hepatic stellate cells are non-parenchymal hepatic cells (cells that constitute the liver other than hepatocytes, which have functions such as storing vitamin A and are present in the space of Disse, which is the region between hepatocytes and sinusoids in the liver). Hepatic stellate cells may be, for example, primary cells (primary hepatic stellate cells) collected from the liver of an animal (e.g., human), cultured cells, cultured cell lines established from primary cells, or cells artificially differentiated from stem cells. An example of primary hepatic stellate cells is primary hepatic stellate cells manufactured by Sciencell, model number 5300. An example of a cultured cell line is a cultured cell line such as LX-2. Examples of stem cells to be differentiated include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), and mesenchymal stem cells. The hepatic stellate cells contained in the cell structure of this embodiment may be non-cancerous cells.

[0024] The ratio (X3 / X0×100) of the number of hepatic stellate cells (X3) to the total number of cells (X0) in the cell structure may be 1% or more, 2% or more, 3% or more, 4% or more, or 5% or more, or may be 20% or less, 15% or less, 14% or less, 13% or less, 12% or less, or 11% or less. From the viewpoint of being even more suitable as hepatoid tissue, the ratio (X3 / X0×100) of the number of hepatic stellate cells (X3) to the total number of cells (X0) in the cell structure may be 1% or more and 15% or less, or 3% or more and 12% or less.

[0025] In this embodiment, the cells may include cells other than hepatocytes, vascular endothelial cells, and hepatic stellate cells. The other cells may be, for example, mature somatic cells or undifferentiated cells such as stem cells. Specific examples of somatic cells include nerve cells, dendritic cells, immune cells, lymphatic endothelial cells, fibroblasts, epithelial cells (excluding hepatocytes), cardiac myocytes, pancreatic islet cells, smooth muscle cells, bone cells, alveolar epithelial cells, and spleen cells. Examples of stem cells include ES cells, iPS cells, and mesenchymal stem cells. The other cells may be normal cells or cells with enhanced or suppressed cell functions, such as cancer cells. "Cancer cells" are cells that are derived from somatic cells and have the ability to proliferate indefinitely.

[0026] The cells in the cell structure may or may not contain mesenchymal stem cells as other cells. The ratio (X4 / X0×100) of the number of mesenchymal stem cells (X4) to the total number of cells (X0) in the cell structure may be 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, or 45% or more, or may be 80% or less, 70% or less, 60% or less, or 55% or less.

[0027] The origin of the hepatocytes, vascular endothelial cells, hepatic stellate cells, or other cells contained therein is not particularly limited, but may be, for example, cells derived from mammals such as humans, monkeys, dogs, cats, rabbits, pigs, cows, mice, and rats.

[0028] The cells in the cell structure according to this embodiment do not need to include cells induced to differentiate from induced pluripotent stem cells (iPS cells). If the cells in the cell structure according to this embodiment do not include cells induced to differentiate from iPS cells, it becomes easier to understand the degree of differentiation from iPS cells, the proportion of differentiated cells relative to the total cells, and the like, and as a result, it becomes even easier to understand the content of each cell constituting the cell structure.

[0029] In the cell structure according to this embodiment, blood vessels are formed between at least some of the cells. "Blood vessels are formed between the cells" means that tubular structures formed by vascular endothelial cells extend between the cells. The cell structure may have gaps between the cells where no blood vessels are formed. The gaps may be empty spaces, or may be filled with extracellular matrix components or the like.

[0030] It is difficult to maintain an artificially produced thick cell structure without blood vessels, and it is believed that oxygen and other nutrients must be supplied from the outside. In contrast, the cell structure according to this embodiment has blood vessels formed between the cells, just like living tissue, and is therefore expected to be able to be maintained for a long period of time. It is also expected to be more likely to engraft when transplanted into mammals, etc.

[0031] The cell structure according to this embodiment preferably has a hepatic sinusoidal network between cells. "Having a hepatic sinusoidal network" means that the tubular structures formed by vascular endothelial cells have a network-like structure in which the tubular structures branch and surround the cells. The intercellular vascular structure and the hepatic sinusoidal network can be confirmed by immunohistochemical staining. For example, the cell structure may have a hepatic sinusoidal network to the extent that, when observed under a microscope from above, it is observed to have multiple branching points and form a network structure.

[0032] (extracellular matrix components) The cell structure according to this embodiment includes extracellular matrix components, which are arranged between at least some of the cells.

[0033] As used herein, the term "extracellular matrix component" refers to an assembly of extracellular matrix molecules formed by multiple extracellular matrix molecules. Extracellular matrix refers to a substance present outside cells in an organism. Any substance can be used as the extracellular matrix as long as it does not adversely affect cell growth and cell aggregate formation. Specific examples include, but are not limited to, collagen, elastin, proteoglycan, fibronectin, hyaluronic acid, laminin, vitronectin, tenascin, entactin, fibrillin, and cadherin. The extracellular matrix component may be used alone or in combination. The extracellular matrix component may, for example, contain a collagen component or may be a collagen component. When the extracellular matrix component is a collagen component, the collagen component functions as a scaffold for cell adhesion, further promoting the formation of a three-dimensional cell structure. In this embodiment, the extracellular matrix component is preferably a substance present outside animal cells, i.e., an animal extracellular matrix component. In addition, the extracellular matrix molecule may be a modified or variant of the above-mentioned extracellular matrix molecule, or may be a polypeptide such as a chemically synthesized peptide, as long as it does not adversely affect cell growth and cell aggregate formation.

[0034] The extracellular matrix component may have repeats of a Gly-XY sequence, which is characteristic of collagen. Here, Gly represents a glycine residue, and X and Y each independently represent any amino acid residue. Multiple Gly-XY residues may be the same or different. Having repeats of a Gly-XY sequence reduces constraints on the molecular chain arrangement, resulting in improved scaffold function. In an extracellular matrix component having repeats of a Gly-XY sequence, the proportion of Gly-XY sequences in the total amino acid sequence may be 80% or more, preferably 95% or more. The extracellular matrix component may also have an RGD sequence. The RGD sequence refers to a sequence represented by Arg-Gly-Asp (arginine residue-glycine residue-aspartic acid residue). When an extracellular matrix component has an RGD sequence, cell adhesion is further promoted, making it even more suitable as a scaffold. Extracellular matrix components containing a sequence represented by Gly-XY and an RGD sequence include collagen, fibronectin, vitronectin, laminin, cadherin, and the like.

[0035] Examples of the shape of the extracellular matrix components include fibrous shapes. Fibrous shapes refer to shapes composed of thread-like extracellular matrix components or shapes composed of thread-like extracellular matrix components cross-linked intermolecularly. At least a portion of the extracellular matrix components may be fibrous. The shape of the extracellular matrix component refers to the shape of a single extracellular matrix component (aggregate of extracellular matrix components) observed under a microscope, and the extracellular matrix component preferably has an average diameter and / or average length as described below. Fibrous extracellular matrix components include thin thread-like materials (thin fibrils) formed by the aggregation of multiple thread-like extracellular matrix molecules, thread-like materials formed by the further aggregation of thin fibrils, and defibrillated versions of these thread-like materials. When fibrous extracellular matrix components are included, the RGD sequences in the fibrous extracellular matrix components are preserved without being destroyed, allowing the scaffold to function more effectively as a scaffold for cell adhesion.

[0036] The extracellular matrix component may include a fragmented extracellular matrix component. "Fragmentation" refers to breaking down an aggregate of extracellular matrix components into smaller sizes. The fragmented extracellular matrix component may include a defibrated extracellular matrix component. A defibrated extracellular matrix component is a component obtained by defibrating the above-mentioned extracellular matrix component by applying a physical force. For example, defibration is performed under conditions that do not break the bonds within the extracellular matrix molecules.

[0037] Fragmented extracellular matrix components can be produced, for example, by a method including a step of fragmenting extracellular matrix components (fragmentation step).

[0038] The method for fragmenting extracellular matrix components is not particularly limited, and fragmentation may be performed by the application of physical force. Unlike enzymatic treatment, the molecular structure of extracellular matrix components fragmented by the application of physical force usually remains unchanged from that before fragmentation (the molecular structure is maintained). The method for fragmenting extracellular matrix components may be, for example, a method for finely crushing clumped extracellular matrix components. Extracellular matrix components may be fragmented in a solid phase or in an aqueous medium. For example, extracellular matrix components may be fragmented by the application of physical force using an ultrasonic homogenizer, a stirring homogenizer, or a high-pressure homogenizer. When a stirring homogenizer is used, the extracellular matrix components may be homogenized directly or in an aqueous medium such as physiological saline. Furthermore, millimeter-sized or nanometer-sized fragmented extracellular matrix components can be obtained by adjusting the homogenization time, number of times, etc. When fragmenting extracellular matrix components in an aqueous medium, the fragmented extracellular matrix components can be produced, for example, by a method comprising the steps of fragmenting the extracellular matrix components in an aqueous medium and removing the aqueous medium from a solution containing the fragmented extracellular matrix components and the aqueous medium (removal step). The removal step may be carried out, for example, by freeze-drying. "Removing the aqueous medium" does not mean that no moisture is attached to the fragmented extracellular matrix components, but rather means that moisture is removed to a degree that can reasonably be achieved by the above-mentioned general drying techniques.

[0039] The diameter and length of fragmented extracellular matrix components can be determined by analyzing individual fragmented extracellular matrix components by electron microscopy.

[0040] The average length of the fragmented extracellular matrix components may be 100 nm or more and 400 μm or less, or 100 nm or more and 200 μm or less. In one embodiment, from the viewpoint of facilitating the formation of thick cell structures, the average length of the fragmented extracellular matrix components may be 5 μm or more and 400 μm or less, 10 μm or more and 400 μm or less, or 100 μm or more and 400 μm or less. In another embodiment, the average length of the fragmented extracellular matrix components may be 100 μm or less, 50 μm or less, 30 μm or less, 15 μm or less, 10 μm or less, 1 μm or less, or 100 nm or more. It is preferable that the average length of the majority of the fragmented extracellular matrix components as a whole is within the above-mentioned numerical range. Specifically, it is preferable that the average lengths of 50% or more of the fragmented extracellular matrix components are within the above-mentioned range, and it is even more preferable that the average lengths of 95% of the fragmented extracellular matrix components are within the above-mentioned range. The fragmented extracellular matrix components are preferably fragmented collagen components having an average length within the above-mentioned range.

[0041] The average diameter of the fragmented extracellular matrix component may be 50 nm to 30 μm, 4 μm to 30 μm, or 5 μm to 30 μm. The fragmented extracellular matrix component is preferably a fragmented collagen component having an average diameter within the above range.

[0042] The average length and average diameter of fragmented extracellular matrix components can be determined by measuring individual fragmented extracellular matrix components using an optical microscope or the like and analyzing the images. As used herein, "average length" refers to the average length of the measured sample in the longitudinal direction, and "average diameter" refers to the average length of the measured sample in the direction perpendicular to the longitudinal direction.

[0043] The fragmented collagen component is also called "fragmented collagen component." The "fragmented collagen component" refers to a collagen component, such as a fibrous collagen component, that has been fragmented and that maintains its triple helix structure. The average length of the fragmented collagen component is preferably 100 nm to 200 μm, more preferably 22 μm to 200 μm, and even more preferably 100 μm to 200 μm. The average diameter of the fragmented collagen component is preferably 50 nm to 30 μm, more preferably 4 μm to 30 μm, and even more preferably 20 μm to 30 μm.

[0044] At least a portion of the extracellular matrix components may be intermolecularly or intramolecularly crosslinked. The extracellular matrix components may be crosslinked intramolecularly or intermolecularly among the extracellular matrix molecules that make up the extracellular matrix components. When the extracellular matrix components include fragmented extracellular matrix components, at least a portion of the fragmented extracellular matrix components may be crosslinked intermolecularly or intramolecularly.

[0045] Extracellular matrix components at least some of which are intermolecularly or intramolecularly crosslinked can be produced, for example, by a method including a step of crosslinking the extracellular matrix components (crosslinking step). The extracellular matrix components can include, for example, fragmented and crosslinked extracellular matrix components. The fragmented and crosslinked extracellular matrix components can be produced, for example, by a method including, in this order, a step of fragmenting the extracellular matrix components and a step of crosslinking the fragmented extracellular matrix components, or a method including, in this order, a step of crosslinking the extracellular matrix components and a step of fragmenting the crosslinked extracellular matrix components.

[0046] Examples of crosslinking methods include physical crosslinking by applying heat, ultraviolet light, radiation, etc., and chemical crosslinking using a crosslinking agent, enzyme reaction, etc., but the method is not particularly limited. From the viewpoint of not interfering with cell growth, physical crosslinking is preferred. Crosslinking (physical crosslinking and chemical crosslinking) may be crosslinking via a covalent bond.

[0047] When the extracellular matrix component contains a collagen component, crosslinks may be formed between collagen molecules (triple helix structure) or between collagen fibrils formed by the collagen molecules. Crosslinking may be thermal crosslinking (thermal crosslinking). Thermal crosslinking can be performed, for example, by heat treatment under reduced pressure using a vacuum pump. When thermal crosslinking of a collagen component is performed, the extracellular matrix component may be crosslinked by forming a peptide bond (-NH-CO-) between an amino group of the collagen molecule and a carboxy group of the same or another collagen molecule.

[0048] Extracellular matrix components can also be crosslinked using a crosslinking agent. The crosslinking agent may be, for example, one capable of crosslinking carboxyl groups with amino groups, or one capable of crosslinking amino groups with each other. Aldehyde-based, carbodiimide-based, epoxide-based, and imidazole-based crosslinking agents are preferred from the standpoints of economy, safety, and ease of use. Specific examples of crosslinking agents include water-soluble carbodiimides such as glutaraldehyde, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and 1-cyclohexyl-3-(2-morpholinyl-4-ethyl)carbodiimide sulfonate.

[0049] The degree of crosslinking can be determined as appropriate depending on the type of extracellular matrix component, the crosslinking method, etc. The degree of crosslinking may be 1% or more, 2% or more, 4% or more, 8% or more, or 12% or more, or 30% or less, 20% or less, or 15% or less. A crosslinking degree within the above range allows the extracellular matrix molecules to be adequately dispersed, and also provides good redispersibility after dry storage.

[0050] When amino groups in the extracellular matrix components are used for crosslinking, the degree of crosslinking can be quantified using the TNBS (2,4,6-trinitrobenzenesulfonic acid) method described in Acta Biomaterialia, 2015, vol. 25, pp. 131-142, etc. The degree of crosslinking measured by the TNBS method may be within the above-mentioned range. The degree of crosslinking measured by the TNBS method is the proportion of amino groups used for crosslinking among the amino groups in the extracellular matrix. When the extracellular matrix components include collagen components, the degree of crosslinking measured by the TNBS method is preferably within the above-mentioned range.

[0051] The degree of crosslinking may be calculated by quantifying the carboxyl groups. For example, in the case of a water-insoluble extracellular matrix component, the degree of crosslinking may be quantified by the TBO (toluidine blue O) method. The degree of crosslinking measured by the TBO method may be within the above-mentioned range.

[0052] In the crosslinking step, the temperature (heating temperature) and time (heating time) for heating the extracellular matrix components can be appropriately determined. The heating temperature may be, for example, 100°C or higher, 200°C or lower, or 220°C or lower. Specific examples of the heating temperature include 100°C, 110°C, 120°C, 130°C, 140°C, 150°C, 160°C, 170°C, 180°C, 190°C, 200°C, and 220°C. The heating time (the time for maintaining the heating temperature) can be appropriately determined depending on the heating temperature. For example, when heating at 100°C to 200°C, the heating time may be 6 hours or longer and 72 hours or shorter, more preferably 24 hours or longer and 48 hours or shorter. In the crosslinking step, heating may be performed in the absence of a solvent or under reduced pressure.

[0053] The content of extracellular matrix components in the cell structure may be, based on the dry weight of the cell structure, 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 2% by mass or more, 3% by mass or more, 4% by mass or more, 5% by mass or more, 6% by mass or more, 7% by mass or more, 8% by mass or more, 9% by mass or more, 10% by mass or more, 15% by mass or more, 20% by mass or more, 25% by mass or more, or 30% by mass or more, or may be 90% by mass or less, 80% by mass or less, 70% by mass or less, 60% by mass or less, 50% by mass or less, 30% by mass or less, 20% by mass or less, or 15% by mass or less. The content of extracellular matrix components in the cell structure may be 0.01 to 90 mass%, 10 to 90 mass%, 10 to 80 mass%, 10 to 70 mass%, 10 to 60 mass%, 1 to 50 mass%, 10 to 50 mass%, 10 to 30 mass%, or 20 to 30 mass%, based on the dry weight of the cell structure.

[0054] Here, "extracellular matrix components in a cell structure" means extracellular matrix components that constitute the cell structure, and may be derived from endogenous extracellular matrix components or exogenous extracellular matrix components.

[0055] "Endogenous extracellular matrix components" refer to extracellular matrix components produced by extracellular matrix-producing cells. Examples of extracellular matrix-producing cells include the above-mentioned mesenchymal cells such as fibroblasts, chondrocytes, and osteoblasts. Endogenous extracellular matrix components may be fibrous or non-fibrous.

[0056] "Exogenous extracellular matrix components" refer to extracellular matrix components supplied from the outside. The cell structure according to this embodiment contains fragmented extracellular matrix components, which are exogenous extracellular matrix components. The exogenous extracellular matrix components may be derived from the same or different animal species as the endogenous extracellular matrix components. Examples of animal species include humans, pigs, and cows. The exogenous extracellular matrix components may also be artificial extracellular matrix components.

[0057] When the extracellular matrix component is a collagen component, the exogenous extracellular matrix component is also referred to as an "exogenous collagen component." The "exogenous collagen component," meaning a collagen component supplied from the outside, is an aggregate of collagen molecules formed by a plurality of collagen molecules, and specific examples thereof include fibrous collagen and non-fibrous collagen. The exogenous collagen component is preferably fibrous collagen. The fibrous collagen refers to a collagen component that is the main component of collagen fibers, and examples thereof include type I collagen, type II collagen, and type III collagen. The fibrous collagen may be commercially available, and a specific example thereof is type I collagen derived from porcine skin manufactured by Nippon Meat Packers, Inc. An example of exogenous non-fibrous collagen is type IV collagen.

[0058] The exogenous extracellular matrix components may be derived from a different animal species than the cells. Also, when the cells include extracellular matrix-producing cells, the exogenous extracellular matrix components may be derived from a different animal species than the extracellular matrix-producing cells. In other words, the exogenous extracellular matrix components may be heterologous extracellular matrix components.

[0059] That is, when a cell structure contains endogenous extracellular matrix components and fragmented extracellular matrix components, the content of extracellular matrix components constituting the cell structure means the total amount of endogenous extracellular matrix components and fragmented extracellular matrix components. The content of extracellular matrix components can be calculated from the volume of the obtained cell structure and the mass of the decellularized cell structure.

[0060] For example, when the extracellular matrix component contained in a cell structure is a collagen component, the amount of collagen component in the cell structure can be quantified, for example, by quantifying hydroxyproline as follows. A lysis solution containing the cell structure is mixed with hydrochloric acid (HCl), incubated at high temperature for a predetermined time, then returned to room temperature. After centrifugation, the supernatant is diluted to a predetermined concentration to prepare a sample. A hydroxyproline standard solution is treated in the same manner as the sample and then serially diluted to prepare standards. The sample and standard are each treated as required with a hydroxyproline assay buffer and a detection reagent, and the absorbance at 570 nm is measured. The amount of collagen component is calculated by comparing the absorbance of the sample with the standard. Alternatively, the cell structure may be directly suspended in high-concentration hydrochloric acid, the resulting lysis solution is centrifuged, and the supernatant is recovered and used for quantification of collagen component. The cell structure to be lysed may be in the state it was recovered from the culture medium, or it may be lysed after recovery and drying to remove the liquid components. However, when quantifying collagen components by dissolving cell structures in the state they have been recovered from the culture medium, it is expected that the measured weight of the cell structures will vary due to the influence of medium components absorbed by the cell structures and residual medium due to problems with the experimental technique. Therefore, from the viewpoint of stably measuring the weight of the tissue and the amount of collagen components per unit weight, it is preferable to use the weight after drying as the basis.

[0061] More specifically, the method for quantifying the amount of collagen component includes, for example, the following method. (Sample preparation) The entire freeze-dried cell structure is mixed with 6 mol / L HCl and incubated in a heat block at 95°C for at least 20 hours, then returned to room temperature. After centrifugation at 13,000 g for 10 minutes, the supernatant of the sample solution is collected. After diluting with 6 mol / L HCl appropriately so that the results fall within the range of the calibration curve in the measurement described below, the sample is prepared by diluting 200 μL with 100 μL of ultrapure water. 35 μL of sample is used.

[0062] (Standard Preparation) Add 125 μL of the standard solution (1200 μg / mL in acetic acid) and 125 μL of 12 mol / L HCl to a screw-cap tube, mix, and incubate at 95°C in a heat block for 20 hours. Then, return the mixture to room temperature. After centrifugation at 13,000×g for 10 minutes, dilute the supernatant with ultrapure water to make S1 (300 μg / mL). Then, serially dilute S1 to make S2 (200 μg / mL), S3 (100 μg / mL), S4 (50 μg / mL), S5 (25 μg / mL), S6 (12.5 μg / mL), and S7 (6.25 μg / mL). Also prepare S8 (0 μg / mL) containing 90 μL of 4 mol / L HCl alone.

[0063] (Assay) Add 35 μL of each standard and sample to a plate (included in the QuickZyme Total Collagen Assay kit, QuickZyme Biosciences). Add 75 μL of assay buffer (included in the kit) to each well. Seal the plate and incubate at room temperature for 20 minutes with shaking. Remove the seal and add 75 μL of detection reagent (reagent A:B = 30 μL:45 μL, included in the kit) to each well. Seal the plate, mix the solution by shaking, and incubate at 60°C for 60 minutes. Cool thoroughly on ice, remove the seal, and measure the absorbance at 570 nm. The amount of collagen component is calculated by comparing the sample absorbance with the standard.

[0064] The collagen component in the cell structure may be defined by its area ratio or volume ratio. "Defining by area ratio or volume ratio" means, for example, making the collagen component in the cell structure distinguishable from other tissue constituents using a known staining method (e.g., immunostaining using an anti-collagen antibody or Masson's trichrome staining), and then calculating the ratio of the area where the collagen component is present in the entire cell structure using macroscopic observation, various microscopes, image analysis software, etc. When defining by area ratio, there are no limitations on which cross section or surface in the cell structure is used to define the area ratio. For example, if the cell structure is a sphere, it may be defined by a cross section passing through the approximate center of the cell structure.

[0065] For example, when the collagen component in a cell structure is defined by its area ratio, the area ratio is typically 0.01 to 99%, and may be 1 to 99%, 5 to 90%, 7 to 90%, 20 to 90%, 30 to 90%, or 50 to 90% of the total area of the cell structure. The "collagen component in a cell structure" is as described above. The area ratio of the collagen component constituting the cell structure refers to the combined area ratio of the endogenous collagen component and the exogenous collagen component. The area ratio of the collagen component can be calculated, for example, by staining the obtained cell structure with Masson's trichrome and calculating the ratio of the area of the blue-stained collagen component to the total area of a cross section passing through approximately the center of the cell structure.

[0066] (polymer electrolyte) The cell structure according to one embodiment may further contain a polyelectrolyte. A polyelectrolyte is a polymer compound having electrolytic properties. Examples of polyelectrolytes include glycosaminoglycans such as heparin, chondroitin sulfate (e.g., chondroitin 4-sulfate, chondroitin 6-sulfate), heparan sulfate, dermatan sulfate, keratan sulfate, and hyaluronic acid; dextran sulfate, rhamnan sulfate, fucoidan, carrageenan, polystyrene sulfonic acid, polyacrylamide-2-methylpropane sulfonic acid, and polyacrylic acid, or derivatives thereof, but are not limited to these. The polyelectrolyte may consist of one of the above-mentioned compounds, or may contain two or more of them in combination.

[0067] The polyelectrolyte is preferably a glycosaminoglycan, more preferably at least one selected from the group consisting of heparin, dextran sulfate, chondroitin sulfate, and dermatan sulfate, and even more preferably heparin. When the cell structure contains a polyelectrolyte, excessive aggregation of extracellular matrix components can be more effectively suppressed, and as a result, cell structures with excellent responsiveness to hepatotoxic substances can be more easily obtained. When the cell structure contains heparin, this effect becomes even more pronounced.

[0068] The ratio (C2 / C1) of the mass C2 of the polyelectrolyte to the mass C1 of the extracellular matrix component may be 1 / 100 to 100 / 1, 1 / 10 to 10 / 1, 1 / 5 to 5 / 1, or 1 / 2 to 2 / 1, or may be 1 / 1.5 to 1.5 / 1.

[0069] (cell structure) The thickness of the cell structure may be 10 μm or more, 30 μm or more, 50 μm or more, 100 μm or more, 300 μm or more, or 1000 μm or more. Such cell structures have a structure closer to that of living tissue and are suitable as substitutes for laboratory animals and transplant materials. The upper limit of the thickness of the cell structure is not particularly limited, but may be, for example, 10 mm or less, 3 mm or less, 2 mm or less, 1.5 mm or less, or 1 mm or less.

[0070] Here, the "thickness of the cell structure" means the distance between both ends in the direction perpendicular to the main surface when the cell structure is sheet-shaped or rectangular. When the main surface has irregularities, the thickness means the distance at the thinnest part of the main surface.

[0071] When the cell structure is spherical or approximately spherical, the thickness of the cell structure refers to the diameter of the cell structure. When the cell structure is ellipsoidal or approximately ellipsoidal, the thickness of the cell structure refers to the minor axis of the cell structure. When the cell structure is approximately spherical or approximately ellipsoidal and has an uneven surface, the thickness of the cell structure refers to the shortest distance between the two points where a line passing through the center of gravity of the cell structure intersects with the surface.

[0072] The cell structure preferably contains fragmented extracellular matrix components and / or polyelectrolytes, which makes the cell structure even more suitable as a tissue model for evaluating hepatotoxicity.

[0073] (fibrin) The cell structure according to this embodiment may contain fibrin. Fibrin is a component produced when thrombin acts on fibrinogen, releasing the A and B chains from the N-termini of the Aα and Bβ chains. Fibrin is a polymer that is generally insoluble in water. Fibrin is formed by contacting fibrinogen with thrombin.

[0074] The cell structure according to this embodiment is constructed in a cell culture vessel. The cell culture vessel is not particularly limited as long as it is capable of constructing a cell structure and culturing the constructed cell structure. Specific examples of the cell culture vessel include dishes, cell culture inserts (e.g., Transwell (registered trademark) inserts, Netwell (registered trademark) inserts, Falcon (registered trademark) cell culture inserts, Millicell (registered trademark) cell culture inserts, etc.), tubes, flasks, bottles, plates, etc. When constructing a cell structure, dishes or various cell culture inserts are preferred from the viewpoint of enabling more appropriate evaluation using the cell structure.

[0075] [Method of manufacturing cell structures] The method for producing a cell structure according to this embodiment comprises a contacting step of contacting cells, including at least hepatocytes and vascular endothelial cells, with an extracellular matrix component in an aqueous medium, and a culturing step of culturing the cells contacted with the extracellular matrix component. The cells and extracellular matrix component may be as described above. In the method for producing a cell structure according to this embodiment, the contacting step may be performed under conditions that suppress aggregation of the extracellular matrix component in the aqueous medium, and the culturing step may be performed under conditions suitable for culturing non-parenchymal hepatic cells.

[0076] (contact process) In the contacting step, cells including at least hepatocytes and vascular endothelial cells are contacted with an extracellular matrix component in an aqueous medium. Contacting the cells with the extracellular matrix component is expected to facilitate the formation of a three-dimensional cell structure.

[0077] Contact between cells and extracellular matrix components may be carried out, for example, under conditions that suppress aggregation of the extracellular matrix components in the aqueous medium. Contact between cells and extracellular matrix components under such conditions further facilitates the formation of a hepatic sinusoidal network in the cell structure. When the cells in the cell structure include hepatocytes, the hepatocytes tend to adhere to each other, which tends to reduce the gaps between the cells, making it difficult for a tubular structure like a hepatic sinusoidal network to form. Contact between cells and extracellular matrix components under conditions that suppress excessive aggregation of the extracellular matrix components in the aqueous medium is presumed to result in a more uniform distribution of the extracellular matrix components and cells in the cell structure, which in turn facilitates the formation of a hepatic sinusoidal network and makes it easier to obtain a cell structure with excellent responsiveness to hepatotoxic substances.

[0078] The aggregation of extracellular matrix components in an aqueous medium can be inhibited, for example, by the presence of a component (e.g., the polyelectrolyte described above) that inhibits aggregation of the extracellular matrix components together with the extracellular matrix components, and / or by using fragmented extracellular matrix components as at least a portion of the extracellular matrix components. Conditions under which aggregation of extracellular matrix components in an aqueous medium is inhibited may be, for example, conditions under which a polyelectrolyte is present and / or conditions under which the extracellular matrix components include fragmented extracellular matrix.

[0079] The term "aqueous medium" refers to a liquid containing water as an essential component. The aqueous medium may be, for example, an aqueous medium containing a cationic substance. The aqueous medium containing a cationic substance may be, for example, a cationic buffer solution such as Tris-hydrochloric acid buffer, Tris-maleic acid buffer, Bis-Tris buffer, or HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), or a medium containing water and a cationic compound such as ethanolamine, diethanolamine, triethanolamine, polyvinylamine, polyallylamine, polylysine, polyhistidine, or polyarginine as the cationic substance. Alternatively, a culture medium may be used as the aqueous medium. Examples of the culture medium include liquid media such as Dulbecco's Modified Eagle Medium (DMEM) and vascular endothelial cell-specific medium (EGM2). The liquid medium may also be a mixed medium obtained by mixing two types of media.

[0080] The concentration and pH of the cationic substance (e.g., Tris in Tris-HCl buffer) in the aqueous medium containing the cationic substance are not particularly limited, as long as they do not adversely affect cell growth and the construction of cell structures. For example, the concentration of the cationic substance may be 10 to 100 mM, 40 to 70 mM, or 50 mM, based on the total amount of the aqueous medium containing the cationic substance. The pH of the aqueous medium (e.g., cationic buffer) may be 6.0 to 8.0, 6.8 to 7.8, or 7.2 to 7.6.

[0081] Examples of the contacting step include a method of mixing an aqueous medium containing extracellular matrix components with a culture medium containing cells under conditions in which aggregation of the extracellular matrix components in the aqueous medium is suppressed, a method of adding an aqueous medium containing extracellular matrix components to a culture medium containing cells, a method of adding cells to an aqueous medium containing extracellular matrix components, and a method of adding the extracellular matrix components and the cells to a pre-prepared aqueous medium.

[0082] The order in which the cells are contacted with the extracellular matrix component is not particularly limited. For example, some of the cells may be contacted with the extracellular matrix component, and then the remaining cells may be contacted with the extracellular matrix component, or all of the cells may be contacted with the extracellular matrix component simultaneously or approximately simultaneously.

[0083] The aqueous medium containing the cells and extracellular matrix may or may not be mixed by stirring after the addition of each substance. The contacting step may include incubating the cells and extracellular matrix components for a certain period of time after contacting them.

[0084] The contacting step may be performed after the cells have been accumulated in an aqueous medium. That is, the contacting step may be performed by accumulating the cells in an aqueous medium and then contacting the cells with an extracellular matrix component. Contacting the accumulated cells with the extracellular matrix component facilitates the production of a cell structure having a high cell density in the lower layer. The cells can be accumulated by, for example, centrifugation, natural sedimentation, or other methods.

[0085] In the contacting step, the ratio of the number of hepatocytes (X1) to the total number of cells (X0) (X1 / X0×100) may be 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, or 65% or more, and may be 95% or less, 90% or less, 80% or less, or 75% or less. In the contacting step, the ratio of the number of hepatocytes (X1) to the total number of cells (X0) (X1 / X0×100) may be 60% or more and 80% or less, or 60% or more and 70% or less, from the viewpoint of being more suitable as hepatoid tissue.

[0086] In the contacting step, the ratio (X2 / X0×100) of the number of vascular endothelial cells (X2) to the total number of cells (X0) may be 5% or more, 10% or more, 12% or more, 14% or more, 15% or more, 20% or more, or 25% or more, or may be 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, or 18% or less. From the viewpoint of being even more suitable as hepatoid tissue, the ratio (X2 / X0×100) of the number of vascular endothelial cells (X2) to the total number of cells (X0) in the cell structure may be 5% or more and 40% or less, 5% or more and 35%, 10% or more and 35%, 10% or more and 25% or less, or 12% or more and 20% or less.

[0087] When the cells include hepatic stellate cells, in the contacting step, the ratio (X3 / X0×100) of the number of hepatic stellate cells (X3) to the total number of cells (X0) may be 1% or more, 2% or more, 3% or more, 4% or more, or 5% or more, or may be 20% or less, 15% or less, 14% or less, 13% or less, 12% or less, or 11% or less. From the viewpoint of being even more suitable as hepatoid tissue, the ratio (X3 / X0×100) of the number of hepatic stellate cells (X3) to the total number of cells (X0) in the cell structure may be 1% or more and 15% or less, or 3% or more and 12% or less.

[0088] In the contacting step, the ratio (X5 / X0×100) of the number of cells other than hepatocytes, vascular endothelial cells, and hepatic stellate cells (X5) to the total number of cells (X0) may be 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, or 45% or more, or may be 80% or less, 70% or less, 60% or less, or 55% or less. The ratio of the number of mesenchymal stem cells (X4) to the total number of cells in the contacting step may be within the above range.

[0089] The cells are preferably not derived from iPS cells. When non-iPS cell-derived cells are used, the type and content of cells in the cell structure can be more easily identified, making the cell structure more suitable as a tissue model for evaluating hepatotoxicity.

[0090] The concentration of the extracellular matrix components in the contacting step can be appropriately determined depending on the shape and thickness of the desired cell structure, the size of the culture vessel, etc. For example, the concentration of the extracellular matrix components in the aqueous medium in the contacting step may be 0.1 to 90% by mass, or 1 to 30% by mass.

[0091] The amount of extracellular matrix components in the contact step is, for example, 1.0 × 10 6 The amount of fragmented extracellular matrix components in the contacting step may be within the above ranges relative to the number of cells, or may be 0.1 to 100 mg, 0.5 to 50 mg, 0.8 to 25 mg, 1.0 to 10 mg, 1.0 to 5.0 mg, 1.0 to 2.0 mg, or 1.0 to 1.8 mg, or 0.7 mg or more, 1.1 mg or more, 1.2 mg or more, 1.3 mg or more, or 1.4 mg or more, or 7.0 mg or less, 3.0 mg or less, 2.3 mg or less, 1.8 mg or less, 1.7 mg or less, 1.6 mg or less, or 1.5 mg or less.

[0092] In the contacting step, the mass ratio of extracellular matrix components to cells (extracellular matrix components / cells) is preferably 1 / 1 to 1000 / 1, more preferably 9 / 1 to 900 / 1, and even more preferably 10 / 1 to 500 / 1.

[0093] In the first embodiment, the contacting step may be, for example, a step of mixing the cells, an extracellular matrix component, and a polyelectrolyte in an aqueous medium (contacting step A).

[0094] The polyelectrolyte may be any of those described above. For example, the concentration of the polyelectrolyte may be more than 0 mg, 0.001 mg or more, 0.005 mg or more, 0.01 mg or more, 0.025 mg or more, 0.05 mg or more, or 0.075 mg or more, or may be less than 1.0 mg, 0.5 mg or less, or 0.1 mg or less, per mL of the total amount of the aqueous medium.

[0095] The first contacting step may be carried out, for example, by mixing an extracellular matrix component-containing solution containing an extracellular matrix component and a first aqueous medium with a polyelectrolyte-containing solution containing a polyelectrolyte and a second aqueous medium, and cells. In the extracellular matrix component-containing solution, the extracellular matrix component may be dissolved or dispersed in the first aqueous medium. In the polyelectrolyte-containing solution, the polyelectrolyte may be dissolved in the second aqueous medium. The first aqueous medium and the second aqueous medium may be the same type of aqueous medium or different types of aqueous media.

[0096] The order in which the extracellular matrix component-containing solution, the polyelectrolyte-containing solution, and the cells are mixed is not particularly limited, and they may be mixed in any order. For example, the extracellular matrix component-containing solution and the polyelectrolyte-containing solution may be mixed in advance to prepare a mixed solution, and the mixed solution may be mixed with the cells. Alternatively, all of them may be mixed substantially simultaneously.

[0097] The content of the extracellular matrix components in the extracellular matrix component-containing liquid may be 0.001 to 1.5 mg / mL, 0.05 to 1.5 mg / mL, or 0.1 to 1.0 mg / mL relative to the total volume of the extracellular matrix component-containing liquid.

[0098] In the polymer electrolyte-containing liquid, the content of the polymer electrolyte may be 0.001 to 10.0 mg / mL, 0.05 to 5.0 mg / mL, or 0.1 to 1.0 mg / mL relative to the total amount of the polymer electrolyte-containing liquid.

[0099] The ratio (A1:A2) of the mass A1 of the polymer electrolyte to the mass A2 of the extracellular matrix component in the contacting step may be 1:200 to 200:1, 1:100 to 100:1, 1:10 to 10:1, 1:5 to 5:1, 1:2 to 2:1, 1:1.5 to 1.5:1, or 1:1.

[0100] In the second embodiment, the contacting step may be a step of contacting cells with fragmented extracellular matrix components (contacting step B). The fragmented extracellular matrix components described above can be used. The second contacting step may be carried out by using fragmented extracellular matrix components as part or all of the extracellular matrix components.

[0101] The contacting step or the step after the contacting step and before the culturing step may include adding fibrinogen and / or thrombin. For example, fibrinogen and thrombin may be added simultaneously, or one may be added first, followed by the other. In the contacting step, for example, a first liquid containing extracellular matrix components, an aqueous medium, and fibrinogen may be mixed with a second liquid containing cells, an aqueous medium, and thrombin. Adding fibrinogen and / or thrombin can more easily suppress shrinkage that may occur in the culturing step described below, making it easier to control the shape and size of the cell structure. Furthermore, the suspension of cells and extracellular matrix components can be gelled, making it easier to maintain a uniform mixture of the cells and extracellular matrix components and to maintain the cells and extracellular matrix components in close proximity to each other.

[0102] The contacting step may include concentrating the cells and extracellular matrix components after contacting the cells with the extracellular matrix components. Concentrating these components results in a more uniform distribution of the extracellular matrix components and cells in the cell structure. Methods for concentrating the cells and extracellular matrix components include, for example, centrifuging a culture solution containing the extracellular matrix components and the cells, and allowing them to settle naturally.

[0103] (Culture process) In the culturing step, cells that have been brought into contact with extracellular matrix components are cultured. The culturing of cells that have been brought into contact with the extracellular matrix is carried out under conditions suitable for culturing non-parenchymal hepatic cells. Conditions suitable for culturing non-parenchymal hepatic cells refer to conditions under which cells other than hepatic cells (e.g., sinusoidal endothelial cells) tend to grow more easily than hepatic cells. The culturing step may be carried out, for example, by culturing the cells in a medium containing a medium for non-parenchymal hepatic cells, or by culturing the cells in a medium that does not contain a medium for hepatic cells and contains a medium for non-parenchymal hepatic cells.

[0104] The medium used in the culturing step may not contain insulin or transferrin, which are proteins secreted from the liver. Examples of the medium used in the culturing step include vascular endothelial medium (e.g., EGM2 (manufactured by Lonza), EGM2-MV (manufactured by Lonza), Endothelial Cell Growth Medium 2 (manufactured by Promocell), Endothelial Cell Growth Medium MV 2 (manufactured by Promocell), and ECM (manufactured by Sciencell). The medium may be a serum-supplemented medium or a serum-free medium. The medium may also be a mixed medium obtained by mixing two types of medium. For example, the medium may be a mixed medium obtained by mixing a vascular endothelial medium and a medium for growing mesenchymal stem cells.

[0105] The culturing step may be carried out in the presence of an angiogenesis promoting factor. A medium containing an angiogenesis promoting factor may be used as the medium for culturing the cells. Examples of angiogenesis promoting factors include vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).

[0106] The culture temperature in the culture step may be, for example, 20° C. to 40° C., or 30° C. to 37° C. The pH of the medium may be 6 to 8, or 7.2 to 7.4. The culture time may be 1 day to 2 weeks, or 1 week to 2 weeks.

[0107] The culture vessel (support) is not particularly limited and may be, for example, a dish, a well insert, a low-adhesion plate, or a plate with a U-shaped or V-shaped bottom. The cells may be cultured while attached to the support, or may be cultured without being attached to the support, or may be detached from the support during the culture process and then cultured. When culturing the cells without being attached to the support, or when culturing the cells after being detached from the support during the culture process, it is preferable to use a plate with a U-shaped or V-shaped bottom that inhibits cell adhesion to the support, or a low-adhesion plate.

[0108] The cell density in the medium in the culture step can be appropriately determined depending on the shape and thickness of the desired cell structure, the size of the culture vessel, etc. For example, the cell density in the medium in the culture step can be set to 1 to 10 8 cells / mL, and 3 ~10 7 The cell density in the medium in the culturing step may be the same as the cell density in the aqueous medium in the contacting step.

[0109] After the above-mentioned culture step (hereinafter also referred to as the "first culture step"; the initial contact step is also referred to as the "first contact step"), a step of contacting cells (second contact step) and a step of culturing the cells (second culture step) may be included. The cells in the second contact step and second culture step may be of the same species as the cells used in the first contact step and first culture step, or may be of a different species. A two-layered cell structure can be produced by the second contact step and second culture step. Furthermore, by repeatedly including the contact step and culture step, a multi-layered cell structure can be produced, and tissues that are more similar to those of a more complex living organism can also be produced.

[0110] According to the manufacturing method of this embodiment, it is possible to suitably manufacture a cell structure in which blood vessels are formed between cells and a cell structure in which hepatic sinusoidal networks are formed between cells.

[0111] [Uses of cell structures] The cell structure of this embodiment can be used as a substitute for experimental animals, transplant material, etc., and specific examples include tissue reconstruction, pathological in vitro models, pharmaceutical screening (drug evaluation), and cosmetic assay screening.

[0112] [Method for evaluating the hepatotoxicity of test substances] The cell structure according to this embodiment has excellent responsiveness to substances having hepatotoxicity, and can therefore be suitably used as a tool for evaluating the presence or absence or degree of hepatotoxicity of a test substance. By using the cell structure according to this embodiment, it becomes easier to obtain a more reliable evaluation of the hepatotoxicity of a test substance. By using the method for evaluating the hepatotoxicity of a test substance using the cell structure according to this embodiment, it is also possible to screen for substances having hepatotoxicity.

[0113] The method for evaluating the hepatotoxicity of a test substance according to this embodiment includes a culturing step of culturing the above-described cell structure in contact with the test substance. The method for evaluating hepatotoxicity is not particularly limited and can be appropriately selected depending on the mechanism of toxicity of interest, such as other assay methods (MTT assay, MTS assay, etc.) that can obtain values correlated with the number of surviving cells, ATP content, albumin production, or viable cell count of the cell structure, methods such as quantifying the amount of bile acid uptake by hepatocytes or quantifying glutathione, or the use of markers such as ALT and bilirubin that are used in clinical evaluations of liver damage.

[0114] In the method for evaluating the hepatotoxicity of a test substance according to this embodiment, the presence or degree of hepatotoxicity may be evaluated, for example, using the number of surviving cells of the cell structure, the amount of albumin produced, or the adenosine triphosphate (ATP) content after the culture process as indicators.

[0115] In the evaluation step, the presence or degree of hepatotoxicity may be evaluated using the hepatic sinusoidal network (vascular network) of the cell structure after the culture step as an index. When the hepatic sinusoidal network is used as an index, specifically, for example, the degree of fragmentation of the hepatic sinusoidal network and / or the total vascular length of the hepatic sinusoidal network may be used as an index.

[0116] In the culturing step, contact between the cell structure and the test substance can be achieved, for example, by adding the test substance to the culture medium for the cell structure.

[0117] The test substance may be, for example, a drug suspected of having hepatotoxic properties.

[0118] The test substance to be evaluated may be one type or two or more types. When two or more types of compounds are evaluated as test substances, each compound may be contacted with a cell structure and evaluated, or multiple compounds may be contacted with a cell structure and evaluated simultaneously.

[0119] The culturing step may be carried out by culturing the cell structure in a medium containing the test substance. The time for culturing the cell structure in the medium containing the test substance is not particularly limited, and may be, for example, 24 to 96 hours, 48 to 96 hours, or 48 to 72 hours. If necessary, hydrodynamic stress such as reflux may be applied, as long as it does not significantly change the culture environment.

[0120] The presence or absence or degree of hepatotoxicity can be evaluated using the number of surviving cells of the cell structure after the culture step as an index, for example, by the following method.

[0121] When the number of viable hepatocytes in the cell structure is lower (low viability) compared to when the cell structure is cultured in the absence of the test substance, the test substance is assessed as toxic to the hepatocytes contained in the cell structure, i.e., hepatotoxic. The greater the decrease in hepatocyte viability compared to when the test substance is absent, the stronger the hepatotoxicity can be assessed. On the other hand, when the number of viable hepatocytes is the same or significantly higher (the same or higher viability) compared to when cultured in the absence of the test substance, the test substance is assessed as not hepatotoxic.

[0122] The viable cell count of hepatocytes can be assessed using a signal correlated with the viable cell count or the abundance of hepatocytes. It is sufficient to measure the viable cell count of hepatocytes at the time of assessment; it is not necessary to measure the cells while they are still alive. For example, hepatocytes can be labeled to distinguish them from other cells, and the signal from the label can be used as an indicator for examination. For example, hepatocytes can be fluorescently labeled and then assessed for viability, thereby directly counting the viable hepatocytes in the cell structure. Image analysis techniques can also be used in this case. Cell viability can be assessed using known cell viability assessment methods, such as trypan blue staining and PI (propidium iodide) staining. Fluorescent labeling of hepatocytes can be performed using known techniques, such as immunostaining, in which an antibody against a substance specifically expressed on the cell surface of hepatocytes is used as a primary antibody and a fluorescently labeled secondary antibody that specifically binds to the primary antibody. The viability assessment and viable cell count can be performed in the cell structure or after the cell structure has been disrupted to the single-cell level. For example, after labeling hepatocytes and dead cells, the three-dimensional structure of the cell structure can be destroyed, and then only the hepatocytes that were alive at the time of evaluation can be directly counted using FACS (fluorescence activated cell sorting) using the label as an indicator.

[0123] The number of viable hepatocytes in the cell structure can also be measured over time by labeling the hepatocytes in the cell structure while they are still alive and detecting the signal from the label over time. The hepatocytes in the cell structure may be labeled after the cell structure is constructed, or the hepatocytes may be labeled in advance before the cell structure is constructed. In addition, when hepatocytes that constitutively express a fluorescent dye are used, the number of viable hepatocytes can also be evaluated by lysing the cell structure and measuring the fluorescence intensity of the lysate obtained using a microplate reader or the like.

[0124] The presence or absence or degree of hepatotoxicity can be evaluated using the amount of albumin produced by the cell structure after the culturing step as an index, for example, by the following method.

[0125] If the amount of albumin produced in the cell structure is low (low albumin production ability) or the ATP content in the cell structure is low compared to when cultured in the absence of the test substance, the test substance is evaluated as being toxic to the hepatocytes contained in the cell structure at that concentration, i.e., hepatotoxic. The greater the decrease in albumin production or ATP content compared to when cultured in the absence of the test substance, the stronger the hepatotoxicity can be evaluated. On the other hand, if the amount of albumin produced is the same or significantly higher (same or higher albumin production ability) or the ATP content is the same or significantly higher compared to when cultured in the absence of the test substance, the test substance is evaluated as not being hepatotoxic at that concentration.

[0126] The amount of albumin produced can be evaluated, for example, by measuring albumin in the culture supernatant using ELISA.

[0127] The hepatocytes contained in the cell construct preferably share a common genotype for at least one drug-metabolizing enzyme, and more preferably share a common genotype for all drug-metabolizing enzymes. Because hepatotoxicity tends to depend on drug-metabolizing enzymes, the use of a cell construct containing hepatocytes with homozygous genotypes for drug-metabolizing enzymes allows for more accurate evaluation of hepatotoxicity.

[0128] A method for evaluating the presence or degree of hepatotoxicity using the hepatic sinusoidal network in the cell structure as an indicator after the culture step can be carried out, for example, by a method including a step of quantifying the total vascular length of the hepatic sinusoidal network in the cell structure after the culture step. Quantifying the total vascular length of the hepatic sinusoidal network can be carried out, for example, by the method described in the Examples below. The method for evaluating the hepatotoxicity of a test substance according to this embodiment can evaluate hepatotoxicity using the hepatic sinusoidal network in the cell structure as an indicator, thereby making it possible to evaluate the presence or degree of hepatotoxicity of a test substance with even higher sensitivity. The method for evaluating the hepatotoxicity of a test substance according to this embodiment is particularly effective when evaluating a test substance that is suspected to affect the hepatic sinusoidal network. [Example]

[0129] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to these examples.

[0130] To prepare the cell construct, the following cells and media were prepared. (cell) Human hepatocytes: Phoenix Bio's PXB cells Human mesenchymal stem cells (MSCs): Lonza product number PT-2501 Liver sinusoidal endothelial cells (SEC): Sciencell, product number 5000 Hepatic stellate cells (Lx2): Merck Millipor, product number SCC064 (Culture medium) Mesenchymal stem cell proliferation medium: Product name MSCGM2, product code C28009, manufactured by Promocell Endothelial medium 1: Product name: ECM, Product code: 1001, manufactured by Sciencell Vascular endothelial medium 2: Product name EGM2-MV, product code CC-3202, manufactured by Lonza Hepatocyte medium: Product name: d-HCGM, Product code: PPC-M200, manufactured by Phoenix Bio

[0131] <Test Example 1: Preparation of cell structure 1> Heparin (Sigma) was dissolved in 20 mM Tris-HCl buffer (pH 7.4) to obtain a heparin solution. The heparin content was 1.0 mg / mL based on the total mass of the heparin solution. Collagen (type I collagen, Nippi) was dissolved in 5 mM acetic acid solution to obtain a collagen solution. The collagen content was 0.4 mg / mL based on the total mass of the collagen solution.

[0132] A mixture of 100 μL of heparin solution and 100 μL of collagen solution was placed in a microtube, and PXB cells, SECs, Lx2, and, if necessary, MSCs were added and suspended. The cell numbers of each type of cell were adjusted to the ratios shown in Table 1. The total number of cells per well was approximately 100,000 cells.

[0133] The resulting suspension was centrifuged at 25°C and 400 × g for 1 minute. This resulted in the formation of a viscous mass with collagen and heparin attached to the cell surface. After stretching, the supernatant was removed, and 250 μL of a mixed medium (1:1 mass ratio) of endothelial cell medium 1 (ECM) and mesenchymal stem cell growth medium (MSCGM2) was added to the microtube. The resulting suspension was then seeded into a 96-well cell culture insert (Roche Inc., E-PlateInsert 16). After seeding, the cells were cultured for a predetermined period in a CO2 incubator (37°C, 5% CO2) to obtain cell constructs.

[0134] [Table 1]

[0135] Figures 1 to 3 are photographs showing the observation results of the cell structures of Examples 1 to 3. Figure 1 shows the observation results of a sample of Example 1 that was fixed on day 7 from the start of culture and then immunostained with CD31 and albumin. Figure 2 shows the observation results of a sample of Example 2 that was fixed on day 8 from the start of culture and then immunostained with CD31 and albumin. Figure 3 shows the observation results of a sample of an Example that was fixed on day 8 from the start of culture and then immunostained with CD31 and albumin. The cell structures shown in Figures 1 to 3 had hepatic sinusoidal reticulum.

[0136] <Test Example 2: Preparation of cell structure 2> [Preparation of defibrated collagen components] A collagen component in which at least a portion was cross-linked (cross-linked collagen component) was obtained by heating 100 mg of porcine skin-derived collagen type I sponge fragments (manufactured by Nippon Meat Packers, Inc.) at 200°C for 24 hours. No significant changes in the appearance of the collagen were observed before and after heating at 200°C. 50 mg of the cross-linked collagen component was placed in a 15 mL tube, 5 mL of ultrapure water was added, and the mixture was homogenized for 6 minutes using a homogenizer (VH-10, AS ONE Corporation).

[0137] The homogenized aqueous solution containing the cross-linked collagen component was centrifuged at 10,000 rpm for 10 minutes at 21°C. The supernatant was aspirated, and the collagen pellet was mixed with 5 mL of fresh ultrapure water to prepare a collagen solution. The tube containing the collagen solution was sonicated at 100 V for 20 seconds using a sonicator (Sonics and Materials, VC50) while kept on ice. After removing the sonicator, the tube containing the collagen solution was cooled on ice for 10 seconds, and this cycle was repeated 100 times. After 100 cycles of sonication, the collagen solution was filtered through a 40 μm pore size filter to obtain a dispersion containing defibrated collagen component (sCMF). The dispersion was lyophilized by conventional methods to obtain the defibrated collagen component (sCMF) as a dry product. The average length of the sCMF was 14.8 ± 8.2 μm (N = 20).

[0138] [Creation of cell structures] Dispersion A was obtained by dispersing the above-mentioned defibrated collagen component in serum-containing medium (DMEM) containing 10 mg / mL fibrinogen (Sigma) to a concentration of 30 mg / mL. Dispersion B was obtained by dispersing cells in serum-containing medium (DMEM) containing 10 U / mL thrombin (Sigma) to a total cell count of 30,000 cells per well. Dispersion A (defibrated collagen component) and Dispersion B were mixed 1:1, and 10 μL of this suspension was added per well to a 48-well plate. Observation results of the culture containing cells and defibrated collagen component 6 days after the start of culture are shown in Figures 4 to 6.

[0139] The culture media used were a mixture of vascular endothelial medium 1 (ECM) and mesenchymal stem cell proliferation medium (MSCGM2) (mass ratio: 1:1), vascular endothelial medium 1 (ECM), or vascular endothelial medium 1 (ECM) and hepatocyte medium (d-HCGM).

[0140] [Table 2]

[0141] When a medium suitable for non-parenchymal liver cells was used, it was confirmed that a sinusoidal network was formed in the cell construct (Examples 4 and 5). On the other hand, when a medium for hepatocytes was used, no sinusoidal network was formed in the obtained cell construct (Comparative Example 1).

[0142] <Test Example 3: Preparation of cell structure 3> A mixture of 100 μL of heparin solution and 100 μL of collagen solution was placed in a microtube, and PXB cells, SECs, Lx2, and, if necessary, MSCs were added and suspended. The cell numbers of each type of cell were adjusted to the ratios shown in Table 3. The total cell number was approximately 30,000 cells.

[0143] The resulting suspension was centrifuged at 25°C and 400 × g for 1 minute. This resulted in the formation of a viscous mass with collagen and heparin attached to the cell surface. After stretching, the supernatant was removed, and 250 μL of a mixed medium (1:1 mass ratio) of endothelial cell medium 1 (ECM) and mesenchymal stem cell growth medium (MSCGM2) was added to the microtube. The resulting suspension was then seeded into a 96-well cell culture insert (Roche Inc., E-PlateInsert 16). After seeding, the cells were cultured for a predetermined period in a CO2 incubator (37°C, 5% CO2) to obtain cell constructs.

[0144] [Table 3]

[0145] As shown in FIGS. 7 and 8, even though the ratio of cell numbers was different from that in Examples 1 to 5, it was confirmed that liver sinusoidal networks were formed in the obtained cell structures.

[0146] <Test Example 4: Preparation of cell structure 4> The cell construct of Example 8 was prepared under the same conditions as in Test Example 1, Condition 1, except that the medium was changed to vascular endothelial medium 2 (EGM2MV) and fixation was performed on day 7 of the culture period. The results are shown in Figure 9. It was confirmed that hepatic sinusoidal network was formed in the cell constructs obtained using different medium.

[0147] <Test Example 5: Measurement of albumin secretion amount> For the cell constructs prepared by the method of Example 1, the amount of albumin secreted was measured by quantifying the amount of albumin in the culture supernatant during the culture period by ELISA. The medium was replaced on the day before the supernatant was collected, and the culture supernatant for 24 hours was used as a sample for ELISA measurement. As a negative control, a cell construct prepared in the same manner as in Example 1 except that it did not contain PXB cells was prepared.

[0148] The measurement results of the amount of albumin secretion are shown in Figure 10. It was confirmed that significant albumin secretion was maintained compared to the negative control 15 days after the start of culture.

[0149] <Test Example 6: Evaluation of hepatotoxicity> In the evaluation test for hepatotoxicity, cell constructs prepared by the methods of Example 5 and Comparative Example 1 and cultured for 7 days were used as the cell constructs for evaluation. Nefazodone and Troglitazone, drugs known to have hepatotoxicity, were used to evaluate hepatotoxicity.

[0150] Seven days after the start of culture, the medium was changed to one containing a drug (Nefazodone or Troglitazone). Ten days after the start of culture, the medium was changed again to one containing a drug, and 14 days later, cell activity was quantified by ATP assay. The results of liver toxicity evaluation are shown in Figures 11 and 12.

[0151] It was confirmed that cell structures having hepatic sinusoidal networks have superior responsiveness to hepatotoxic substances compared to cell structures not having hepatic sinusoidal networks.

[0152] <Test Example 7: Monocrotaline administration experiment> [Preparation of liver model (hepatotoxicity model)] (Recovery of cells other than PXB cells) Frozen stocks of Lx2, SEC, and MSC cells were euthanized and cultured without passaging according to the manufacturer's recommended protocol. After recovery from the culture flasks and dishes using trypsin according to standard methods, the cell mass of each cell was measured.

[0153] (PXB cell recovery) The cells were collected and the cell mass was measured according to the following procedure. PXB cells were washed with PBS. 2 mL of 0.25% trypsin-EDTA was added to the PXB cells and incubated in an incubator. HCGM was then added to the PXB cells and pipetted to recover the PXB cells, which were then counted using a cell counter.

[0154] PXB cells, SEC, and LX2 were mixed to obtain the following ratios and cell amounts to obtain a cell mixture. Total cell count per well: 30,000 cells ·Tissue cell ratio: PXB cells: 65%, SEC: 25%, LX2: 10%

[0155] A heparin-collagen solution was prepared by mixing equal volumes of 1.0 mg / mL heparin solution (buffer: 100 mM Tris-HCl) and 0.3 mg / mL collagen solution (buffer: 5 mM acetate).

[0156] 100 μL of heparin-collagen solution was added to the cell mixture, and the cells were suspended until they could no longer be seen, followed by centrifugation (400 g × 2 min) to form a viscous mass within the solution.

[0157] After removing the supernatant from the solution containing the viscous bodies, 20 U / mL thrombin solution (solvent: HCM (hepatocyte culture medium)) was added so that the final volume of the solution was the number of wells to be seeded x 2 μL, and a cell suspension was obtained.

[0158] A 10 mg / mL fibrinogen solution was placed on a 48-well plate to form droplets, and the cell suspension was added to the droplets.Then, the plate was left to stand in an incubator for 40 minutes to form a fibrin gel.

[0159] To each well in which the fibrin gel had formed, 0.5 mL of HCM (containing Endothelial Cell Growth Supplement) was added to obtain a liver model as a cell structure.

[0160] [Medication to the liver model] One day (Day 1) and four days (Day 4) after the start of liver model culture, the liver model was dosed by replacing the medium with one containing monocrotaline at concentrations of 2000 μM, 666 μM, 222 μM, or 74 μM. The compounds used were dissolved in DMSO at high concentrations and stored, and DMSO was added to the medium at 1% concentration before dosing. Since each dosing condition contained 1% DMSO, a medium change with medium containing only 1% DMSO was also performed at the same time as a negative control.

[0161] [ATP assay in liver models] Seven days after the start of liver model culture (Day 7), an ATP assay was performed using the CellTiter-Glo (registered trademark) 3D Cell Viability Assay kit as follows.

[0162] The compound-containing medium was removed from each well of the 48-well plate, and 100 μL of room-temperature DMEM was added. Then, 100 μL of the ATP assay reagent provided with the kit was added at room temperature. The 48-well plate containing the ATP assay reagent was shaken in a thermostatic shaker (1000 rpm, room temperature) for 5 minutes. The 48-well plate was then left to stand at room temperature for 25 minutes.

[0163] The entire mixture of DMEM and ATP assay reagent was transferred from each well to a 96-well plate for luminescence measurement, and the luminescence intensity was measured using a plate reader.

[0164] [Liver model fixation, immunostaining, and microscopic imaging] For each administered sample, fixation, permeabilization, blocking, primary antibody treatment, secondary antibody treatment, imaging, area calculation, and evaluation were carried out in this order. The procedures from fixation to evaluation are described below.

[0165] (fixation processing) Six days after the start of liver model culture (day 6), the 48-well plate was removed from the incubator, the medium was removed, and the plate was washed with PBS. 300 μL of 4% paraformaldehyde in phosphate buffer (PFA) was then added to each well to fix the liver model. The PFA was then thoroughly washed away.

[0166] (Permeabilization and Blocking) 100 μL of 0.2 (v / v) % TRITON / 1 (w / v) % BSA PBS solution (hereinafter referred to as BSA solution) was added to the insert of each well, and the plate was left to stand at room temperature for 2 hours.

[0167] (Primary antibody treatment) Mouse anti-CD31 antibody was diluted 100-fold with BSA solution to obtain a primary antibody solution. 100 μL of the primary antibody solution was added to each well insert and allowed to stand at 4°C for 24 hours. The primary antibody solution was then thoroughly washed away.

[0168] (Secondary antibody treatment) The secondary antibody was diluted 200-fold with BSA solution to obtain a secondary antibody solution. 100 μL of the secondary antibody solution was added to each well insert and allowed to stand at room temperature for 1 hour in the dark. The secondary antibody solution was then thoroughly washed away, and 100 μL of PBS was added to each well.

[0169] (Fluorescence microscopy) Images were taken using a confocal microscope under the following conditions: Lens used: 4x lens Shooting mode: non-confocal Filter: 647(Ex) / 512(Em) Z-axis position: 0-100μm in 10μm increments

[0170] The intensities of the images taken using the above method were summed to obtain fluorescent observation images of each liver model.

[0171] Image analysis was performed on each captured image using Image J according to the following steps (1) to (10). This resulted in a skeleton image extracted from the original image. The area of the hepatic sinusoidal network (blood vessels) in the skeleton image was extracted using the image cross product. (1)Image > Type > 8-bit (2) Process > Smooth (3)Process > Subtract Background > Sliding Paraboloid (20 pixels) (4)Process > Enhance contrast(Saturated pixels:10.0%, Normalize) (5)Process > Math > Subtract (value:100) (6)Plugins > Mexican hat filter(Radius:5.0) (7)Plugins > Skeleton > Skeletonize(2D / 3D) (8) Image > Adjust > Threshold (Threshold: 1 -255) (9)Process > Analyze particle (Size: >250μm) (10)Analyze > Analyze Skeleton > Analyze Skeleton(2D / 3D)

[0172] Figure 13 shows the results of CD31 immunostaining 7 days (Day 7) after the start of culturing a liver model to which a predetermined concentration of monocrotaline had been administered. 2 13 and 14, it was observed that as the monocrotaline concentration increased, the hepatic sinusoidal network became more fragmented.

[0173] Figure 15 shows the quantification results for the total vessel length of the hepatic sinusoidal network. Figure 16 shows the results of the ATP assay. As shown in Figures 15 and 16, when the hepatic sinusoidal network was quantified (when the amount of damage to the vascular network was quantified), drug efficacy could be evaluated with higher sensitivity than with the ATP assay.

[0174] <Test Example 8: Toxicity evaluation experiment of 18 compounds> Toxicity evaluation of compounds was carried out using a cell construct with hepatic sinusoidal network prepared using CMF (Example A) and a cell construct with hepatic sinusoidal network prepared using heparin and collagen solution (Example B). Toxicity evaluation was carried out by administering the compound to be evaluated and carrying out an ATP assay in the same manner as in Test Example 6.

[0175] The cell structure of Example A was obtained by the method described in Test Example 6.

[0176] The cell structure of Example B was obtained by the method described in Test Example 7.

[0177] Toxicity was evaluated using IC50 and MOS values. MOS values are indices used to evaluate toxicity, taking into account the maximum blood concentration (Cmax).

[0178] Reference Examples A and B are literature values based on Proctor WR et al., Arch Toxicol, 2017, 91, 2849-2863 and the supplementary information therein. Reference Example A is 2D PHH (two-dimensional primary human hepatocytes) in the above literature, and Reference Example B is 3D hLiMT (3D human liver microtissues) in the above literature. The IC50s for Reference Examples A and B are also shown in Tables 4 and 5. It was demonstrated that the cell structures produced by this test example are capable of reproducibly evaluating substances that have been reported to be toxic.

[0179] The table below also shows the drug-induced liver injury severity category (LKBT), where III indicates most DILI concern, II indicates less DILI concern, and I indicates no DILI concern.

[0180] [Table 4] [Table 5]

Claims

1. A method for producing a cell structure having a hepatic sinusoidal network between cells including at least hepatocytes and vascular endothelial cells, comprising: a contacting step of contacting the cells, extracellular matrix components, fibrinogen, and thrombin in an aqueous medium; a culturing step of culturing the cells that have been contacted with the extracellular matrix component, the fibrinogen, and the thrombin, the contacting step is carried out under conditions that suppress aggregation of the extracellular matrix components in the aqueous medium; A method for producing a cell structure, wherein the culturing step is carried out by culturing the cells in a medium that does not contain a medium for hepatocytes and contains a medium for vascular endothelial cells.

2. 2. The method for producing a cell structure according to claim 1, wherein after the cells and the extracellular matrix components are contacted in the aqueous medium, the fibrinogen and the thrombin are contacted with the cells and the extracellular matrix components.

3. The method for producing a cell structure according to claim 1 or 2, wherein the extracellular matrix component is fibrous.

4. The method for producing a cell structure according to any one of claims 1 to 3, wherein the contacting step is carried out by mixing the cells, the extracellular matrix component, and a polyelectrolyte.

5. The method for producing a cell structure according to claim 4, wherein the polyelectrolyte is heparin.

6. A method for producing a cell structure described in any one of claims 1 to 5, wherein the contacting step includes accumulating the cells and the extracellular matrix components after contacting the cells with the extracellular matrix components.

7. The method for producing a cell structure according to any one of claims 1 to 6, wherein the extracellular matrix component comprises a collagen component.

8. The method for producing a cell structure according to any one of claims 1 to 7, wherein the extracellular matrix component comprises a fragmented extracellular matrix component.

9. The method for producing a cell structure according to claim 8 , wherein the fragmented extracellular matrix components are defibrated extracellular matrix components.

10. The method for producing a cell structure according to any one of claims 1 to 9, wherein the vascular endothelial cells are sinusoidal endothelial cells.

11. The method for producing a cell structure according to any one of claims 1 to 10, wherein the cells further comprise hepatic stellate cells.

12. The method for producing a cell structure according to any one of claims 1 to 11, wherein the culturing step is carried out in the presence of an angiogenesis promoting factor.

Images